What is Vayarin®

Vayarin® is an orally administered prescription medical food for the clinical dietary management of certain lipid imbalance associated with ADHD.


The unique composition in Vayarin® is Lipirinen™ 167 mg. Lipirinen™ is a proprietary composition containing phosphatidylserine-omega 3, EPA enriched

Phospholipids, such as phosphatidylserine (PS), are a class of lipids that serve as major building blocks for all cell membranes. PS, a vital phospholipid, plays an important role in the normal functioning of brain cells. Human brain cell membranes are highly enriched with PS, as compared to other tissues. Nerve cells in particular, depend on healthy membrane function for normal nerve signal transmission. PS levels in these tissues ensure membrane fluidity and structure. In fact, maintaining brain PS levels has been found to be associated with normal and efficient signal transduction processes, efficient glucose consumption and other biological pathways that are crucial for ensuring normal and healthy cognitive and mental functions [1-4].

Omega-3 fatty acids are polyunsaturated fatty acids that have been found to have unique and important health benefits. Several studies [5-7] suggest that dietary consumption of omega-3, especially EPA and DHA, affect neuropsychiatric disorders, presumably due to their structural and neurochemical involvement in pathophysiological processes. As the evidence suggests, decreased levels of omega-3 fatty acids have been associated with several neuropsychiatric conditions, including ADHD [7]. The results of VAYA Pharma’s clinical trial [8] further support the beneficial effects of PS -omega-3 compound (Vayarin®) on children with ADHD symptoms (for more information see link: Vayarin Benefits).


  • Vayarin® is available by prescription only and its use must be supervised by a physician (for more information on medical foods, see link).
  • The recommended dose of Vayarin® is two capsules a day or as directed by a physician.


References:

1. McDaniel, M.A., S.F. Maier, and G.O. Einstein, “Brain-specific” nutrients: a memory cure? Nutrition, 2003. 19(11-12) p. 957-75. | 2. Mozzi, R., S. Buratta, and G. Goracci, Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res, 2003. 28(2): p. 195-214. | 3. Pepeu, G., I.M. Pepeu, and L. Amaducci, A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res, 1996. 33(2): p. 73-80. | 4. Vance, J.E. and R. Steenbergen, Metabolism and functions of phosphatidylserine. Prog Lipid Res, 2005. 44(4): p. 207-34. | 5. Hibbeln, J.R., Fish consumption and major depression. Lancet, 1998. 351(9110): p. 1213. | 6. Noaghiul, S. and J.R. Hibbeln, Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry, 2003. 160(12): p. 2222-7. | 7. Young, G. and J. Conquer, Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev, 2005. 45(1): p. 1-28. | 8. Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A., The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry. 2011 Jul 30. [Epub ahead of print]